Ignite Creation Date:
2024-05-06 @ 3:48 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04767841
Status:
RECRUITING
Last Update Posted:
2023-04-11
First Post:
2021-02-16
Brief Title:
The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis
Sponsor:
Sadat City University
Organization:
Sadat City University
Study Overview
Official Title:
The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Patients With Knee Osteoarthritis A Proof-of-Concept Randomized Double-Blind Placebo-Controlled Trial
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
metformin alleviates drug-induced osteoarthritis OA-like change in mice knee joint through activating autophagy and downregulating apoptosis Metformin exerts its protective effects against OA through the AMPKa2 SIRT1 pathway Metformin suppresses IL-1β-induced oxidative and osteoarthritis-like inflammatory changes by enhancing the SIRT3PINK1Parkin signaling pathway thereby indicating metformins potential in prevention and treatment of osteoarthritic joint disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None